Published: June 24, 2018 4:39:21 p. M.
A vaccine used primarily to treat tuberculosis (TB) may be effective in reducing high blood sugar levels among people with type 1 diabetes, the results of a clinical trial revealed.
Type 1 diabetes is a chronic condition in which the pancreas produces little or no insulin.
The findings showed that, three years after receiving two administrations of the Bacillus Calmette-Guerin (BCG) vaccine four weeks apart, people with long-standing type 1 diabetes improved in HbA1c – agglomerated hemoglobin – measure to evaluate sugar levels in general to almost normal levels.
"This is the clinical validation of stable blood sugar potential at near-normal levels with a safe vaccine, even in patients with long-standing disease," said Denise Faustman, director of the Immunobiology Laboratory at Massachusetts General Hospital, USA. United.
The study, published in the journal NPP Vaccine, also reported that the effects of the BCG vaccine on blood sugar control seem to depend on a totally novel metabolic mechanism that increases cellular glucose consumption.
The team analyzed data from 282 human participants in the study: 52 with type 1 diabetes who participated in BCG clinical trials and 230 who contributed blood samples for mechanistic studies.
The results showed that the HbA1c levels of those who received BCG had decreased by more than 10 percent in three years after treatment and by more than 18 percent in four years.
The study demonstrated that vaccination with BCG induces epigenetic reprogramming at the level of the chromatin architecture and functional alterations indicative of a permanent change in immunity.
Therefore, the clinical effects and the proposed mechanism add to the emerging consensus that the BCG vaccine can have a valuable impact on the immune system, the researchers said.
For all the latest lifestyle news, download the Indian Express application